<DOC>
	<DOCNO>NCT00900536</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood and/or tissue laboratory patient kidney cancer receive sorafenib may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict well patient respond sorafenib . PURPOSE : This research study look DNA blood and/or tissue sample patient primary kidney cancer receive sorafenib clinical trial MRC-RE05-SORCE .</brief_summary>
	<brief_title>DNA Analysis Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib Clinical Trial MRC-RE05-SORCE</brief_title>
	<detailed_description>OBJECTIVES : - Examine relationship tumor genotype , expression , patient outcome . - Examine relationship constitutional genotype patient outcome . OUTLINE : This multicenter study . Patients undergo blood and/or tissue sample collection laboratory study . Laboratory study include generation tissue microarrays ; analysis protein expression immunohistochemistry ; tumor DNA extraction whole genome amplification ; detection VHL relevant gene mutation direct sequencing ; constitutional ( lymphocyte DNA ) genotyping single nucleotide polymorphism analysis .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm resect renal cell carcinoma Clear cell nonclear cell tumor Receiving sorafenib tosylate clinical trial MRCRE05SORCE PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>papillary renal cell carcinoma</keyword>
</DOC>